NO20054032L - Glykolipidderivater, fremgangsmate for fremstilling derav, mellomprodukter for fremstilling derav oq fremgangsmater for fremstilling av mellomproduktene. - Google Patents

Glykolipidderivater, fremgangsmate for fremstilling derav, mellomprodukter for fremstilling derav oq fremgangsmater for fremstilling av mellomproduktene.

Info

Publication number
NO20054032L
NO20054032L NO20054032A NO20054032A NO20054032L NO 20054032 L NO20054032 L NO 20054032L NO 20054032 A NO20054032 A NO 20054032A NO 20054032 A NO20054032 A NO 20054032A NO 20054032 L NO20054032 L NO 20054032L
Authority
NO
Norway
Prior art keywords
substituted
unsubstituted
preparation
intermediates
processes
Prior art date
Application number
NO20054032A
Other languages
English (en)
Other versions
NO20054032D0 (no
Inventor
Takashi Yamamura
Hirokazu Annoura
Kenji Murata
Original Assignee
Daiichi Asubio Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Asubio Pharma Co Ltd filed Critical Daiichi Asubio Pharma Co Ltd
Publication of NO20054032D0 publication Critical patent/NO20054032D0/no
Publication of NO20054032L publication Critical patent/NO20054032L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00—Compounds containing azido groups
    • C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/04—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyridine Compounds (AREA)

Abstract

Nye glykolipidderivater, hvor substituenten i sfingosin-basedelen er en alkylgruppe med kort karbonkjede, en substituert eller usubstituert cykloalkylgruppe, substituert eller usubstituert arylgruppe eller substituert eller usubstituert aralkylgruppe; en effektiv prosess for praktisk masseproduksjon derav og mellomprodukter anvendelige for fremstilling derav Spesifikt blir glykolipidderivater representert ved formel (I) kjemisk fremstilt: hvor R3 er substituert eller usubstituert lineær alkyl som har 1 til 7 karbonatomer, substituert eller usubstituert cykloalkyl, substituert eller usubstituert aryl eller substituert eller usubstituert aralkyl og R8 er substituert eller usubstituert alkyl som har 1 til 35 karbonatomer, substituert eller usubstituert aryl eller substituert eller usubstituert aralkyl.
NO20054032A 2003-02-14 2005-08-30 Glykolipidderivater, fremgangsmate for fremstilling derav, mellomprodukter for fremstilling derav oq fremgangsmater for fremstilling av mellomproduktene. NO20054032L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003037397 2003-02-14
PCT/JP2004/001566 WO2004072091A1 (ja) 2003-02-14 2004-02-13 糖脂質誘導体及びその製造法並びにそれらの合成中間体及びその製造法

Publications (2)

Publication Number Publication Date
NO20054032D0 NO20054032D0 (no) 2005-08-30
NO20054032L true NO20054032L (no) 2005-11-01

Family

ID=32866358

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054032A NO20054032L (no) 2003-02-14 2005-08-30 Glykolipidderivater, fremgangsmate for fremstilling derav, mellomprodukter for fremstilling derav oq fremgangsmater for fremstilling av mellomproduktene.

Country Status (12)

Country Link
US (2) US7732583B2 (no)
EP (2) EP1619199B1 (no)
JP (2) JP4742220B2 (no)
KR (1) KR20050105215A (no)
CN (2) CN100537585C (no)
AU (1) AU2004210784A1 (no)
BR (1) BRPI0407501A (no)
CA (1) CA2515396A1 (no)
ES (2) ES2676345T3 (no)
HU (1) HUE037560T2 (no)
NO (1) NO20054032L (no)
WO (1) WO2004072091A1 (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9809654B2 (en) 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
AU2005280163B2 (en) * 2004-08-27 2011-11-24 Albert Einstein College Of Medicine, Inc. Ceramide derivatives as modulators of immunity and autoimmunity
JP5090928B2 (ja) * 2004-12-28 2012-12-05 ザ ロックフェラー ユニバーシティ Ｎｋｔ細胞に対する抗原としての糖脂質及びその類似体
US7923013B2 (en) 2004-12-28 2011-04-12 The Rockefeller University Glycolipids and analogues thereof as antigens for NKT cells
RU2008103792A (ru) * 2005-07-01 2009-08-10 Джапэн Эз Репризентид Бай Президент Оф Нэшнл Сентер Оф Ньюролоджи Энд Сайкайатри (Jp) Производное гликолипидов и лекарственное средство, содержащее это производное в качестве активного компонента
WO2008047174A1 (en) * 2006-10-18 2008-04-24 Centre National De La Recherche Scientifique Alpha-galactosylceramide analogs, their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them
CA2678618C (en) 2007-02-21 2019-03-12 Vaccinex, Inc. Modulation of nkt cell activity with antigen-loaded cd1d molecules
AU2010203451B2 (en) 2009-01-08 2016-06-30 Albert Einstein College Of Medicine, Inc. Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
CN101775051B (zh) * 2010-01-07 2013-03-27 北京大学 一种区域选择性脱除糖o-苄基保护基的方法
US10632740B2 (en) 2010-04-23 2020-04-28 Landa Corporation Ltd. Digital printing process
US10190012B2 (en) 2012-03-05 2019-01-29 Landa Corporation Ltd. Treatment of release layer and inkjet ink formulations
US10434761B2 (en) 2012-03-05 2019-10-08 Landa Corporation Ltd. Digital printing process
WO2015036960A1 (en) 2013-09-11 2015-03-19 Landa Corporation Ltd. Release layer treatment formulations
US10642198B2 (en) 2012-03-05 2020-05-05 Landa Corporation Ltd. Intermediate transfer members for use with indirect printing systems and protonatable intermediate transfer members for use with indirect printing systems
US9498946B2 (en) 2012-03-05 2016-11-22 Landa Corporation Ltd. Apparatus and method for control or monitoring of a printing system
US9381736B2 (en) 2012-03-05 2016-07-05 Landa Corporation Ltd. Digital printing process
EP4019596A1 (en) 2012-03-05 2022-06-29 Landa Corporation Ltd. Method for manufacturing an ink film construction
US9643403B2 (en) 2012-03-05 2017-05-09 Landa Corporation Ltd. Printing system
CN106084986B (zh) 2012-03-05 2019-06-25 兰达公司 油墨膜构造
US9902147B2 (en) 2012-03-05 2018-02-27 Landa Corporation Ltd. Digital printing system
US9643400B2 (en) 2012-03-05 2017-05-09 Landa Corporation Ltd. Treatment of release layer
CN104284850B (zh) 2012-03-15 2018-09-11 兰达公司 打印系统的环形柔性皮带
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
AU2014214770B2 (en) 2013-02-08 2018-09-06 Albert Einstein College Of Medicine Inc. Modified glycolipids and methods of making and using the same
GB201401173D0 (en) 2013-09-11 2014-03-12 Landa Corp Ltd Ink formulations and film constructions thereof
GB2536489B (en) 2015-03-20 2018-08-29 Landa Corporation Ltd Indirect printing system
GB2537813A (en) 2015-04-14 2016-11-02 Landa Corp Ltd Apparatus for threading an intermediate transfer member of a printing system
GB201609463D0 (en) 2016-05-30 2016-07-13 Landa Labs 2012 Ltd Method of manufacturing a multi-layer article
US10933661B2 (en) 2016-05-30 2021-03-02 Landa Corporation Ltd. Digital printing process
JP7206268B2 (ja) 2017-10-19 2023-01-17 ランダ コーポレイション リミテッド 印刷システム用の無端可撓性ベルト
WO2019097464A1 (en) 2017-11-19 2019-05-23 Landa Corporation Ltd. Digital printing system
US11511536B2 (en) 2017-11-27 2022-11-29 Landa Corporation Ltd. Calibration of runout error in a digital printing system
US11707943B2 (en) 2017-12-06 2023-07-25 Landa Corporation Ltd. Method and apparatus for digital printing
JP7273038B2 (ja) 2017-12-07 2023-05-12 ランダ コーポレイション リミテッド デジタル印刷処理及び方法
WO2020003088A1 (en) 2018-06-26 2020-01-02 Landa Corporation Ltd. An intermediate transfer member for a digital printing system
US10994528B1 (en) 2018-08-02 2021-05-04 Landa Corporation Ltd. Digital printing system with flexible intermediate transfer member
JP7305748B2 (ja) 2018-08-13 2023-07-10 ランダ コーポレイション リミテッド デジタル画像にダミー画素を埋め込むことによるデジタル印刷における歪み補正
JP7246496B2 (ja) 2018-10-08 2023-03-27 ランダ コーポレイション リミテッド 印刷システムおよび方法に関する摩擦低減手段
JP7462648B2 (ja) 2018-12-24 2024-04-05 ランダ コーポレイション リミテッド デジタル印刷システム
WO2021105806A1 (en) 2019-11-25 2021-06-03 Landa Corporation Ltd. Drying ink in digital printing using infrared radiation absorbed by particles embedded inside itm
US11321028B2 (en) 2019-12-11 2022-05-03 Landa Corporation Ltd. Correcting registration errors in digital printing
WO2021137063A1 (en) 2019-12-29 2021-07-08 Landa Corporation Ltd. Printing method and system
WO2022102557A1 (ja) * 2020-11-12 2022-05-19 国立研究開発法人理化学研究所 擬似糖脂質誘導体並びにその合成中間体、製造方法及び用途
AU2022228420A1 (en) 2021-03-01 2023-10-05 Deciduous Therapeutics, Inc. Compounds for activating invariant natural killer t-cells and methods of use in eliminating inflammatory senescent cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6072960A (ja) * 1983-09-30 1985-04-25 Sumitomo Chem Co Ltd モノアゾ化合物およびそれを用いて染色または捺染する方法
JPH0559081A (ja) * 1991-08-29 1993-03-09 Kirin Brewery Co Ltd 新規スフインゴ糖脂質、その製造法および使用
US5936076A (en) * 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
EP0666268B1 (en) * 1992-10-22 2000-04-19 Kirin Beer Kabushiki Kaisha Novel sphingoglycolipid and use thereof
JP2002226377A (ja) * 1996-10-14 2002-08-14 Kirin Brewery Co Ltd 配糖体含有末梢血幹細胞増加剤
KR100527950B1 (ko) 1997-04-10 2005-11-09 기린 비루 가부시키가이샤 알파-글리코실세라미드를 함유하는 엔케이티 세포활성화제
CN100439383C (zh) * 2001-08-16 2008-12-03 阿斯比奥制药株式会社 糖脂及其作为有效成分的用于自体免疫疾病的药物

Also Published As

Publication number Publication date
WO2004072091A1 (ja) 2004-08-26
KR20050105215A (ko) 2005-11-03
ES2450043T3 (es) 2014-03-21
EP2343306A1 (en) 2011-07-13
CN101165047A (zh) 2008-04-23
HUE037560T2 (hu) 2018-09-28
JP5246448B2 (ja) 2013-07-24
US20060074235A1 (en) 2006-04-06
WO2004072091B1 (ja) 2004-11-11
CN1768072A (zh) 2006-05-03
AU2004210784A1 (en) 2004-08-26
CN100537585C (zh) 2009-09-09
EP1619199B1 (en) 2013-12-18
JPWO2004072091A1 (ja) 2006-06-01
CA2515396A1 (en) 2004-08-26
EP1619199A1 (en) 2006-01-25
US7732583B2 (en) 2010-06-08
JP2011063593A (ja) 2011-03-31
US20100210828A1 (en) 2010-08-19
JP4742220B2 (ja) 2011-08-10
EP1619199A4 (en) 2009-12-16
ES2676345T3 (es) 2018-07-18
US8034908B2 (en) 2011-10-11
EP2343306B1 (en) 2018-04-04
NO20054032D0 (no) 2005-08-30
BRPI0407501A (pt) 2006-02-14
CN101165047B (zh) 2010-10-20

Similar Documents

Publication Publication Date Title
NO20054032L (no) Glykolipidderivater, fremgangsmate for fremstilling derav, mellomprodukter for fremstilling derav oq fremgangsmater for fremstilling av mellomproduktene.
NO20052887L (no) Pyridazinonderivater som GSK-3Beta inhibitorer.
BG108174A (en) 5-phenylpyrimidines, methods and intermediate products for the production thereof and use of the same for controlling pathogenic fungi
HUP0300080A2 (hu) Új malonsavszármazékok, eljárás előállításukra, ezek alkalmazása Xa faktor inhibitorként és ezeket tartalmazó gyógyszerkészítmények
DK1008592T3 (da) Cykliske amidderivater, som inhiberer cathepsin K
MY143665A (en) Method of producing aminophenol compounds.
NO20031701L (no) Fremgangsmåte og mellomprodukter i fremstilling av 7- substituerte antiöstrogener
EP1634874A4 (en) imidazolidine
BRPI0408160B1 (pt) Processo para o preparo de ésteres do ácido nicotínico substituído e intermediários de enamina para uso nesse processo
NO20055167L (no) Nye benzotiadiazinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
UA87284C2 (ru) Соединения фенилпиридилпиперазина, способ их получения и фармацевтическая композиция, которая их содержит
NO20013643L (no) Fremgangsmåte for fremstilling av optisk aktiv alkohol
TW200619201A (en) Process for the preparation of pyrazoles
NO20082698L (no) Nye derivater, deres salter og antisoppmidler inneholdende disse
NO20091779L (no) Nye indolforbindelser en prosess for deres fremstilling og farmasoytiske sammensetninger som inneholder dem
NO20082005L (no) Syntese av renininhibitorer omfattende en cyklotilfoyelsesreaksjon
CY1105158T1 (el) Εκδοχα πυριδοϊνδολονης που φερει υποκαταστατη στο -3 μια ετepοκυκλικη ομαδα, η παρασκευη τους και η εφαρμογη τους στη θepαπευτικη
NO20055844D0 (no) Nye benzotiazin og benzotiadiazinforbindelsep fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20062100L (no) Nye fenylpyridylpiperazinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
SI1565451T1 (sl) Derivati halotienoil-ciklopropan-1-karboksilne kisline
AR058839A1 (es) Derivados de piperidina, utiles para el tratamiento de enfermedades proliferativas
EP1211253A4 (en) DIHYDROBENZOFURAN TRICYCLIC DERIVATIVES, THEIR PREPARATION METHOD AND AGENTS
BRPI0506548A (pt) métodos para produzir compostos de 4-tetrazolil-4-fenilpiperidina
TW200640845A (en) Method for preparing unsaturated ether compound
NO20045540L (no) Nye 3-(4-okso-4H-kromen-2-yl)-(1H)-kinolin-4-on-forbindelser, en fremgangsmate for deres fremstilling og farmasoytisk sammensetninger inneholdende dem

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application